Spruce Biosciences, Inc. (SPRB)
60.78
-2.52
(-3.98%)
USD |
NASDAQ |
Aug 28, 16:00
60.60
-0.18
(-0.30%)
After-Hours: 20:00
Spruce Biosciences Enterprise Value : 78.69M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 78.69M |
| August 27, 2026 | 85.63M |
| August 26, 2026 | 80.62M |
| August 25, 2026 | 85.90M |
| August 24, 2026 | 72.83M |
| August 21, 2026 | 53.37M |
| August 20, 2026 | 54.48M |
| August 19, 2026 | 57.17M |
| August 18, 2026 | 56.85M |
| August 17, 2026 | 57.06M |
| August 14, 2026 | 56.28M |
| August 13, 2026 | 48.38M |
| August 12, 2026 | 40.95M |
| August 11, 2026 | 39.13M |
| August 10, 2026 | 38.56M |
| August 07, 2026 | 40.40M |
| August 06, 2026 | 39.16M |
| August 05, 2026 | 39.68M |
| August 04, 2026 | 38.72M |
| August 03, 2026 | 30.13M |
| July 31, 2026 | 29.28M |
| July 30, 2026 | 30.77M |
| July 29, 2026 | 25.48M |
| July 28, 2026 | 25.89M |
| July 27, 2026 | 26.97M |
| Date | Value |
|---|---|
| July 24, 2026 | 29.97M |
| July 23, 2026 | 35.23M |
| July 22, 2026 | 34.15M |
| July 21, 2026 | 37.12M |
| July 20, 2026 | 33.88M |
| July 17, 2026 | 31.23M |
| July 16, 2026 | 33.27M |
| July 15, 2026 | 36.46M |
| July 14, 2026 | 39.00M |
| July 13, 2026 | 44.56M |
| July 10, 2026 | 49.21M |
| July 09, 2026 | 53.81M |
| July 08, 2026 | 48.47M |
| July 07, 2026 | 51.14M |
| July 06, 2026 | 54.11M |
| July 02, 2026 | 55.93M |
| July 01, 2026 | 56.02M |
| June 30, 2026 | 60.03M |
| June 29, 2026 | 29.73M |
| June 26, 2026 | 28.67M |
| June 25, 2026 | 25.46M |
| June 24, 2026 | 24.22M |
| June 23, 2026 | 24.59M |
| June 22, 2026 | 28.11M |
| June 18, 2026 | 24.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 39.34B |
| PTC Therapeutics, Inc. | 4.308B |
| ACADIA Pharmaceuticals, Inc. | 4.128B |
| Alnylam Pharmaceuticals, Inc. | 31.39B |
| Anika Therapeutics, Inc. | 269.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.23M |
| Total Expenses (Quarterly) | 16.23M |
| EPS Diluted (Quarterly) | -6.676 |
| Earnings Yield | -67.25% |
| Normalized Earnings Yield | -63.88 |